Phase I Study of IPH1101 (with Low Dose of IL-2) in Patient with B-NHL

Background: Since the discovery of gd-T lymphocytes in the 80s', their particular ability to recognize and kill tumours of haematological origin has been extensively studied. The pioneer clinical study using immunotherapy with activated γδ T cells in oncology (with an aminobisphosphonate associated with low dose IL-2 as γδ activator) was conducted in relapsed/refractory low grade B-NHL patients (Wilhelm et al. 2003), demonstrating an interesting correlation between γδ T cell amplification in vivo and clinical response. In order to further exploit the potential of γδ immunotherapy, we have developed the most specific γδ T lymphocyte ligands, referred to as “phosphoantigens”, IPH1101 being the first ever administered to oncology patients. Upon IPH1101 activation, γδ T cells secrete pro-inflammatory cytokines allowing the implementation of an improved adaptive response. When IPH1101 is associated with low doses of IL-2, γδ T cells proliferate and differentiate into highly potent antitumor effectors. Here, we present the safety, pharmacokinetic and pharmacodynamic profiles of IPH1101 associated with low dose IL-2 in relapsed low grade B-NHL patients.